{"entity":{"id":"nct05374915","kind":"trial","name":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","aka":[],"tldr":"A phase 2 trial of REM-001 photodynamic therapy in advanced solid tumours, run by Kintara Therapeutics, Inc., active and no longer recruiting.","summary":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) is a phase 2 interventional study registered as NCT05374915 by Kintara Therapeutics, Inc., with 15 participants enrolled, started 2024-02-12 and due to reach its primary completion in 2025-12-30. Interventions recorded: REM-001 photodynamic therapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05374915","url":"https://clinicaltrials.gov/study/NCT05374915"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05374915","phase":"2","setting":"An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) That is Refractory or Not Eligible for Radiotherapy or Surgery","sponsor":"Kintara Therapeutics, Inc.","enrolled":15,"outcomes":[]},"route":"/trials/nct05374915/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}